Sign Out
Concor AM is indicated in patients whose blood pressure is adequately controlled with separately administered mono-component preparations of the same doses as the recommended fixed dose combination.
Posology: Recommended daily dose is one tablet of the given strength.
Treatment must not be abruptly discontinued, as it may lead to temporary deterioration of clinical condition. Treatment must not be abruptly discontinued especially in case of patients suffering from ischaemic heart disease. Gradual decrease of the dose is recommended.
Patients with hepatic impairment: In case of hepatic impairment elimination of amlodipine may be elongated. Dosage recommendations concerning amlodipine have not been established in patients with mild to moderate hepatic impairment. The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment.
The drug should therefore be administered with special caution in patients with hepatic impairment (see Precautions).
In case of severe hepatic impairment the daily dose of bisoprolol must not exceed 10 mg.
Patients with renal impairment: No dosage adjustment is required for patients with mild to moderate renal impairment.
Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialyzable (see Precautions). In case of severe renal impairment (creatinine clearance <20 ml/min) the daily dose of bisoprolol must not exceed 10 mg.
Elderly patients: The usual doses can be administered to elderly people; however, caution is advised when the dose is increased (see Pharmacology: Pharmacokinetics under Actions).
Paediatric population: The safety and efficacy of Concor AM in children and adolescents below the age of 18 years have not been established. No data are available.
Method of administration: Concor AM should be taken in the morning with or without food, without chewing it.
Route of Administration: Oral.
